These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
126 related articles for article (PubMed ID: 9422021)
1. Elevation of serum interleukin-1 receptor antagonist levels in women with gynaecological cancers. Fujiwaki R; Hata T; Miyazaki K; Kawamura T; Inada K Br J Obstet Gynaecol; 1997 Dec; 104(12):1407-8. PubMed ID: 9422021 [TBL] [Abstract][Full Text] [Related]
2. [Significantly increased interleukin-1A and interleukin-1 soluble type II receptor levels in women with ovarian cancer]. Kondera-Anasz Z; Mielczarek-Palacz A; Switała J Ginekol Pol; 2003 Sep; 74(9):761-6. PubMed ID: 14674121 [TBL] [Abstract][Full Text] [Related]
3. Cancer-associated serum globulin determined in patients with cervical, endometrial and ovarian cancer. Altarac S Acta Med Croatica; 1993; 47(1):19-22. PubMed ID: 7693081 [TBL] [Abstract][Full Text] [Related]
4. Serum evaluation of P53 protein in patients with gynaecological cancer. Barbati A; Mariani L; Porpora MG; Anceschi M; Collini P; Lauro V; Cosmi EV Anticancer Res; 2000; 20(2A):1033-5. PubMed ID: 10810393 [TBL] [Abstract][Full Text] [Related]
5. Soluble urokinase plasminogen activator receptor in preoperatively obtained plasma from patients with gynecological cancer or benign gynecological diseases. Riisbro R; Stephens RW; Brünner N; Christensen IJ; Nielsen HJ; Heilmann L; von Tempelhoff GF Gynecol Oncol; 2001 Sep; 82(3):523-31. PubMed ID: 11520150 [TBL] [Abstract][Full Text] [Related]
6. Interleukin-6 serum levels in patients with gynecological tumors. Scambia G; Testa U; Panici PB; Martucci R; Foti E; Petrini M; Amoroso M; Masciullo V; Peschle C; Mancuso S Int J Cancer; 1994 May; 57(3):318-23. PubMed ID: 8168990 [TBL] [Abstract][Full Text] [Related]
7. [Clinical significance of vascular endothelial growth factor in sera of patients with gynaecological malignant tumors]. Peng XP; Li JD; Li MD; Ye XM; Yan WC Ai Zheng; 2002 Feb; 21(2):181-5. PubMed ID: 12479072 [TBL] [Abstract][Full Text] [Related]
8. Trends in gynaecological cancers in the largest obstetrics and gynaecology hospital in China from 2003 to 2013. Li X; Zheng S; Chen S; Qin F; Lau S; Chen Q Tumour Biol; 2015 Jul; 36(7):4961-6. PubMed ID: 25649977 [TBL] [Abstract][Full Text] [Related]
9. Clinical significance of serum Dkk-3 in patients with gynecological cancer. Jiang T; Huang L; Wang S; Zhang S J Obstet Gynaecol Res; 2010 Aug; 36(4):769-73. PubMed ID: 20666943 [TBL] [Abstract][Full Text] [Related]
10. Serum level of macrophage colony-stimulating factor as a marker for gynecologic malignancies. Suzuki M; Ohwada M; Sato I; Nagatomo M Oncology; 1995; 52(2):128-33. PubMed ID: 7854772 [TBL] [Abstract][Full Text] [Related]
11. Quantitation of Fas and Fas ligand gene expression in human ovarian, cervical and endometrial carcinomas using real-time quantitative RT-PCR. Das H; Koizumi T; Sugimoto T; Chakraborty S; Ichimura T; Hasegawa K; Nishimura R Br J Cancer; 2000 May; 82(10):1682-8. PubMed ID: 10817504 [TBL] [Abstract][Full Text] [Related]
12. Decreased IL-1 RA concentration in ascites is associated with a significant improvement in overall survival in ovarian cancer. Mustea A; Pirvulescu C; Könsgen D; Braicu EI; Yuan S; Sun P; Lichtenegger W; Sehouli J Cytokine; 2008 Apr; 42(1):77-84. PubMed ID: 18329282 [TBL] [Abstract][Full Text] [Related]
13. Clinical evaluation of serum sialosyl-Tn antigen levels in comparison with CA 125 levels in gynecologic cancers. Ryuko K; Iwanari O; Nakayama S; Iida K; Kitao M Cancer; 1992 May; 69(9):2368-78. PubMed ID: 1562985 [TBL] [Abstract][Full Text] [Related]
14. Concentrations of interleukin (IL)-1alpha, IL-1 soluble receptor type II (IL-1 sRII) and IL-1 receptor antagonist (IL-1 Ra) in the peritoneal fluid and serum of infertile women with endometriosis. Kondera-Anasz Z; Sikora J; Mielczarek-Palacz A; Jońca M Eur J Obstet Gynecol Reprod Biol; 2005 Dec; 123(2):198-203. PubMed ID: 16046047 [TBL] [Abstract][Full Text] [Related]
15. Cytokine production profiles in the peritoneal fluids of patients with malignant or benign gynecologic tumors. Punnonen R; Teisala K; Kuoppala T; Bennett B; Punnonen J Cancer; 1998 Aug; 83(4):788-96. PubMed ID: 9708947 [TBL] [Abstract][Full Text] [Related]
16. Impaired cytokine production in whole blood cell cultures of patients with gynaecological carcinomas in different clinical stages. Elsässer-Beile U; von Kleist S; Sauther W; Gallati H; Mönting JS Br J Cancer; 1993 Jul; 68(1):32-6. PubMed ID: 8318418 [TBL] [Abstract][Full Text] [Related]
17. [Immunosuppressive acidic protein in patients with gynecologic cancer]. Sawada M; Matsui Y; Okudaira Y; Shimizu Y; Takayama K Nihon Sanka Fujinka Gakkai Zasshi; 1983 May; 35(5):605-11. PubMed ID: 6408203 [TBL] [Abstract][Full Text] [Related]
18. The growth response to tumour necrosis factor alpha of human gynaecological cancer cell lines. Beesley JS; Kirby PL; Takeda S; Stackpoole A; Soutter WP; White JO Cytokine; 1998 Jun; 10(6):432-40. PubMed ID: 9632529 [TBL] [Abstract][Full Text] [Related]
19. Surface antigen expression on peripheral blood monocytes in women with gynecologic malignancies. Jóźwik M; Okungbowa OE; Lipska A; Jóźwik M; Smoktunowicz M; Semczuk A; Jóźwik M; Radziwon P BMC Cancer; 2015 Mar; 15():129. PubMed ID: 25880896 [TBL] [Abstract][Full Text] [Related]
20. P16(INK4a) protein expression in endocervical, endometrial and metastatic adenocarcinomas of extra-uterine origin: diagnostic and clinical considerations. Caponio MA; Addati T; Popescu O; Petroni S; Rubini V; Centrone M; Trojano G; Simone G Cancer Biomark; 2014; 14(2-3):169-75. PubMed ID: 24878818 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]